SCHEMBL20164522

SCHEMBL20164522

CCCNc1nc(N(C)C)nc2c(N(C)CC(C)(C)O)ncnc12

nearest known ligand 0.40

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
SLC29A1 Q99808 3/20 0.40
ABL1 P00519 1/20 0.31
SRC P12931 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL20164536 0.99 SLC29A1 (0.39) SLC29A1ABL1SRC
SCHEMBL20164639 0.84 SLC29A1 (0.53) SLC29A1ABL1SRC
Hydrochloric Acid SCHEMBL20164562 0.83 SLC29A1 (0.52) SLC29A1ABL1SRC
SCHEMBL20164646 0.81 SLC29A1 (0.44) SLC29A1ABL1SRC
Hydrochloric Acid SCHEMBL20164760 0.81 SLC29A1 (0.43) SLC29A1ABL1SRC
SCHEMBL20164344 0.78 SLC29A1 (0.47) SLC29A1ABL1SRC
SCHEMBL25378008 0.76 SLC29A1 (0.43) SLC29A1ABL1SRC
SCHEMBL20164445 0.76 SLC29A1 (0.55) SLC29A1
Hydrochloric Acid SCHEMBL20164715 0.75 SLC29A1 (0.42) SLC29A1ABL1SRC
Hydrochloric Acid SCHEMBL20164699 0.75 SLC29A1 (0.53) SLC29A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180141953-A1 Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same NEURAD LTD. (IL) 2018-05-24 US claimed
US-20250057848-A1 GAL475 COMPOSITIONS AND METHODS OF USE THEREOF NEURIM PHARMACEUTICALS (1991) LTD. (IL) 2025-02-20 US disclosed
EP-3316890-B1 NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME NEURAD LTD (IL) 2023-09-06 EP disclosed
US-10294228-B2 Breathing control modulating compounds, and methods of making and using same NEURAD LTD. (IL) 2019-05-21 US disclosed
US-20180141953-A1 Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same NEURAD LTD. (IL) 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141953-A1 Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same MTNR1B, CHRM3, PER2 SLC29A1 4472/4885ABL1 4537/4885SRC 4856/4885
US-20250057848-A1 GAL475 COMPOSITIONS AND METHODS OF USE THEREOF GPR119, GPR35, GPR55 SLC29A1 2077/4885ABL1 4720/4885SRC 4434/4885
US-10294228-B2 Breathing control modulating compounds, and methods of making and using same MTNR1B, PDE3A, CHRM3 SLC29A1 4518/4885ABL1 4346/4885SRC 4821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.